Education
About Us
Working with TipRanks
Follow Us
Contineum Therapeutics, Inc. Class A (CTNM)
NASDAQ:CTNM
CTNM Stock Chart & Stats
$11.76
-$0.71(-5.12%)
At close: 4:00 PM EST
$11.76
-$0.71(-5.12%)
Day’s Range― - ―
52-Week Range$3.35 - $13.57
Previous CloseN/A
Volume54.82K
Average Volume (3M)170.88K
Market Cap
$429.59M
Enterprise Value-$66.93M
Total Cash (Recent Filing)$182.41M
Total Debt (Recent Filing)$5.49M
Price to Earnings (P/E)―
Beta0.58
Next Earnings
Mar 05, 2026EPS Estimate
-0.42Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.45
Shares Outstanding30,446,112
10 Day Avg. Volume105,448
30 Day Avg. Volume170,880
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)1.43
Price to Sales (P/S)0.00
P/FCF Ratio-8.50
Enterprise Value/Market Cap-0.16
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit418.29
Enterprise Value/Ebitda1.09
Forecast
1Y Price Target
$18.60Price Target Upside58.16% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Class Validation Read-throughA positive Phase III readout for an LPA1 antagonist from a large competitor in 2026 would validate the mechanism and likely boost confidence in PIPE-791's commercial prospects.
Clinical Development — IPFAdvancement into a Phase II study for PIPE-791 targeting idiopathic pulmonary fibrosis offers an opportunity to demonstrate a best‑in‑class LPA1 antagonist profile, which could materially increase investor interest.
Financial RunwayDeferring select clinical studies has extended the company's projected financial runway through 2028, reducing near‑term dilution risk and supporting upside potential.
Bears Say
Clinical Setbacks — RRMSThe Phase II VISTA trial of PIPE-307 in relapsing‑remitting multiple sclerosis failed to meet prespecified primary and secondary endpoints, diminishing the drug's outlook in that indication.
Development Risk — MDDLimited probability of success for PIPE-307 in major depressive disorder indicates persistent development risk that could constrain upside until stronger efficacy signals occur.
Valuation PressureRemoval of the RRMS opportunity from financial models led analysts to lower price targets, signaling reduced near‑term valuation and weighing on the share price.
Contineum Therapeutics, Inc. Class A News
CTNM FAQ
What was Contineum Therapeutics, Inc. Class A’s price range in the past 12 months?
Contineum Therapeutics, Inc. Class A lowest stock price was $3.35 and its highest was $13.56 in the past 12 months.
What is Contineum Therapeutics, Inc. Class A’s market cap?
Contineum Therapeutics, Inc. Class A’s market cap is $429.59M.
When is Contineum Therapeutics, Inc. Class A’s upcoming earnings report date?
Contineum Therapeutics, Inc. Class A’s upcoming earnings report date is Mar 05, 2026 which is in 48 days.
How were Contineum Therapeutics, Inc. Class A’s earnings last quarter?
Contineum Therapeutics, Inc. Class A released its earnings results on Oct 30, 2025. The company reported -$0.45 earnings per share for the quarter, beating the consensus estimate of -$0.484 by $0.034.
Is Contineum Therapeutics, Inc. Class A overvalued?
According to Wall Street analysts Contineum Therapeutics, Inc. Class A’s price is currently Undervalued.
Does Contineum Therapeutics, Inc. Class A pay dividends?
Contineum Therapeutics, Inc. Class A does not currently pay dividends.
What is Contineum Therapeutics, Inc. Class A’s EPS estimate?
Contineum Therapeutics, Inc. Class A’s EPS estimate is -0.42.
How many shares outstanding does Contineum Therapeutics, Inc. Class A have?
Contineum Therapeutics, Inc. Class A has 30,446,112 shares outstanding.
What happened to Contineum Therapeutics, Inc. Class A’s price movement after its last earnings report?
Contineum Therapeutics, Inc. Class A reported an EPS of -$0.45 in its last earnings report, beating expectations of -$0.484. Following the earnings report the stock price went up 4.459%.
Which hedge fund is a major shareholder of Contineum Therapeutics, Inc. Class A?
Currently, no hedge funds are holding shares in CTNM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Contineum Therapeutics, Inc. Class A Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$18.60 (58.16% Upside)
$18.60 (58.16% Upside)
Hedge Fund Trend
Increased
By 1.9M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 3.3%
Last 30 Days ▲ 9.3%
Last 30 Days ▲ 9.3%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-32.24%
12-Months-Change
Fundamentals
Return on Equity
-30.40%
Trailing 12-Months
Asset Growth
-17.38%
Trailing 12-Months
Company Description
Contineum Therapeutics, Inc. Class A
Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. Its lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and progressive multiple sclerosis (MS). The company also develops PIPE-307, a novel, small molecule selective inhibitor of the muscarinic type 1 M1 receptor to treat depression and relapse remitting MS; and CTX-343, a peripherally-restricted LPA1R antagonist. Contineum Therapeutics, Inc. was formerly known as Pipeline Therapeutics, Inc. and changed its name to Contineum Therapeutics, Inc. in November 2023. The company was incorporated in 2009 and is headquartered in San Diego, California.
CTNM Stock 12 Month Forecast
Average Price Target
$18.60
▲(58.16% Upside)
Technical Analysis
Tvardi Therapeutics
―
Capricor Therapeutics
―
Alpha Tau Medical Ltd
―
Immuneering
―
enGene Holdings
―
Ownership Overview
0.61% Insiders
7.55% Mutual Funds
34.58% Other Institutional Investors
54.08% Public Companies and
Individual Investors